The survival rate of acute promyelocytic leukemia can reach about 80%, which means that the majority of patients can be clinically cured.
Acute promyelocytic leukemia is a subtype of acute leukemia, and the clinical cure rate of this subtype is relatively high, which is mainly manifested by the high number of promyelocytes found during bone marrow aspiration, and the patients may have infections, hemorrhage, anemia and so on. In addition, this type of leukemia has a characteristic genetic abnormality, i.e., the PML-RARĪ± fusion gene.
Patients with acute promyelocytic leukemia can be tested for the targeted gene and treated with drugs such as all-trans retinoic acid and arsenite under the guidance of a doctor, and about 80% of patients can achieve a relatively good outcome, while only 20% of patients can be endangered by severe bleeding.
For patients with acute promyelocytic leukemia, it is recommended to consult the hematology department of regular hospitals and receive regular treatment under the guidance of physicians.